AbCellera Biologics Inc. (ABCL) financials: revenue, earnings and cash flow
Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
AbCellera Biologics’s revenue went from $12M in fiscal 2019 to $75M in fiscal 2025, growth of about 36.5% a year.
Net income in fiscal 2025 was -$146M, a net margin of -194.9%; the best year in this period was 2022 with $159M.
Over the twelve months to September 30, 2026, revenue was $68M and net income -$148M.
Free cash flow was -$174M in fiscal 2025 and positive in 3 of the 7 years shown.
The diluted share count rose 97% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $68M | $75M | $29M | $38M | $485M | $375M | $233M | $12M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$202M | -$217M | -$315M | -$237M | $217M | $204M | $156M | -$4M |
| Net income | -$148M | -$146M | -$163M | -$146M | $159M | $153M | $119M | -$2M |
| EPS (diluted) | $-0.48 | $-0.49 | $-0.55 | $-0.51 | $0.50 | $0.48 | $0.45 | $-0.01 |
| R&D | $186M | $187M | $167M | $176M | $108M | $62M | $29M | $10M |
| Revenue growth | — | +160.6% | −24.2% | −92.2% | +29.4% | +60.9% | +1907.9% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15M | -$131M | -$109M | -$44M | $277M | $245M | $23M | $3M |
| Capital spending | -$17M | -$43M | -$78M | -$77M | -$71M | -$58M | -$10M | -$4M |
| Free cash flow | -$33M | -$174M | -$187M | -$121M | $207M | $186M | $13M | -$1M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | — | — |
| Buybacks | — | — | — | — | — | — | — | — |
| Stock-based pay | $49M | $56M | $68M | $64M | $49M | $31M | $8M | $890000 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash | — | $129M | $156M | $133M | $387M | $476M | $594M | — |
| Debt | — | $143M | $65M | $77M | $82M | $40M | $4M | — |
| Equity | — | $967M | $1.1B | $1.2B | $1.2B | $1.0B | $831M | $10M |
| Total assets | — | $1.4B | $1.4B | $1.5B | $1.5B | $1.3B | $1.0B | — |
| Shares (diluted) | 318M | 299M | 294M | 289M | 315M | 318M | 263M | 151M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -298.0% | -289.0% | -1091.7% | -623.8% | 44.6% | 54.5% | 66.9% | -35.4% |
| Net margin | -218.5% | -194.9% | -564.8% | -385.0% | 32.7% | 40.9% | 51.0% | -19.0% |
| FCF margin | -48.4% | -231.7% | -648.4% | -317.8% | 42.6% | 49.6% | 5.6% | -11.2% |
| ROIC | — | -16.1% | -22.8% | -16.2% | 10.9% | 13.4% | 14.1% | -31.7% |
| ROE | — | -15.1% | -15.4% | -12.7% | 12.8% | 15.0% | 14.3% | -21.6% |
Frequently asked questions
What is AbCellera Biologics’s annual revenue?
$75M in fiscal 2025 and $68M over the twelve months to September 30, 2026.
How much profit does AbCellera Biologics make?
Net income was -$146M in fiscal 2025 (net margin -194.9%).
Is AbCellera Biologics’s revenue growing?
Yes: revenue rose 160.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.